STRS Ohio’s Janux Therapeutics JANX Stock Holding History

STRS Ohio’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,600	Closed	-$246K	–	1972
2024 Q4	$246K	Buy	4,600 +2,700	+142%	+$143K	﹤0.01%	1434
2024 Q3	$86.3K	Buy	+1,900	New	+$82.7K	﹤0.01%	1732
2021 Q4	–	Sell	-3,000	Closed	-$64K	–	2254
2021 Q3	$64K	Buy	+3,000	New	+$86.3K	﹤0.01%	2026

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

STRS Ohio's JANX Position: Q1 2025 in Review

STRS Ohio sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 4,600 shares — an estimated $246K sold.

STRS Ohio first reported a position in JANX in Q3 2021 and held it in 3 quarters. The position peaked at $246K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

STRS Ohio reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
STRS Ohio sold 4,600 Janux Therapeutics shares in Q1 2025, an estimated $246K.
STRS Ohio first reported a position in Janux Therapeutics in Q3 2021 and held it in 3 quarters.
STRS Ohio's Janux Therapeutics position peaked at $246K in Q4 2024.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on STRS Ohio's 13F filing for Q1 2025, filed 28 May 2025.